Citizens Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Citizens Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$245K	Sell	4,281 -634	-13%	-$34.7K	﹤0.01%	916
2026 Q1	$278K	Buy	+4,915	New	+$287K	﹤0.01%	714
2020 Q3	–	Sell	-85	Closed	-$10K	–	331
2020 Q2	$10K	Hold	85	–	–	﹤0.01%	766
2020 Q1	$7K	Sell	85 -82	-49%	-$7.07K	﹤0.01%	804
2019 Q4	$14K	Buy	167 +115	+221%	+$8.69K	﹤0.01%	681
2019 Q3	$4K	Hold	52	–	–	﹤0.01%	694
2019 Q2	$4K	Buy	+52	New	+$4.45K	﹤0.01%	678

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Citizens Financial Group's BMRN Position: Q2 2026 in Review

Citizens Financial Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 13% in Q2 2026, selling an estimated $34.7K and leaving 4,281 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #916.

Citizens Financial Group first reported a position in BMRN in Q2 2019 and has held it in 7 quarters since. The position peaked at $278K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Citizens Financial Group held 4,281 shares of BioMarin Pharmaceuticals worth $245K as of Q2 2026.
Citizens Financial Group sold 634 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $34.7K.
BioMarin Pharmaceuticals made up ﹤0.01% of Citizens Financial Group's portfolio in Q2 2026, its #916 holding.
Citizens Financial Group first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 7 quarters since.
Citizens Financial Group's BioMarin Pharmaceuticals position peaked at $278K in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Citizens Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.